E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 8/11/2017 in the Prospect News Canadian Bonds Daily, Prospect News Distressed Debt Daily and Prospect News High Yield Daily.

Concordia has $301.8 million of cash to meet needs for the year

By Devika Patel

Knoxville, Tenn., Aug. 11 – Concordia International Corp. has enough cash – $301.8 million - and cash flow to meet its needs for the year ahead.

“At the present time, we believe that cash and cash equivalents as of June 30, 2017, along with positive cash flows from operations, will be sufficient to meet current liquidity needs [for] at least the next 12 months,” chief financial officer David Price said on the company’s second quarter earnings conference call on Friday.

As of June 30, liquidity was substantially comprised of $301.8 million of cash and cash equivalents. The $301.8 million cash position compares to $397.9 million of cash at the same time last year.

Second quarter adjusted EBITDA was $81.8 million, compared to $142.3 million for the same period in 2016, and $84.2 million in the first quarter of 2017.

Oakville, Ont.-based Concordia International makes legacy pharmaceutical acquisitions and develops orphan drugs.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.